Shiquan Chang

Shiquan Chang

Auto-generated profile, based on publicly available information

Shiquan Chang

College of Traditional Chinese Medicine Jinan University Guangzhou China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2022 in Phytotherapy Research
Verified
Journal Article
Open access
SCShiquan Chang
Shiquan Chang
XLXin Li
Xin Li
YZYachun Zheng
Yachun Zheng
HSHuimei Shi
Huimei Shi
Di ZhangDi Zhang
Di Zhang
GZGuoping Zhao
Guoping Zhao
Switching microglial polarization from the M1 to M2 phenotype is a promising therapeutic strategy for neuropathic pain (NP). Toll‐like receptor 4 (TLR4) is activated by lipopolysaccharide (LPS). Uncontrolled activation of TLR4 has been proven to trigger chronic inflammation. Kaempferol, a dietary flavonoid, is known to have anti‐inflammatory properties. This study is aimed to investigate the analgesic and anti‐inflammatory effects and the underlying mechanisms of kaempferol, which were explored with an NP model in vivo and LPS‐induced injury in microglial BV2 cells in vitro. The levels of proinflammatory cytokines were evaluated. H&E staining and immunohistochemistry were used to assess the sciatic nerve condition after chronic constriction injury surgery. Western blotting and immunofluorescence were used to determine whether TLR4/NF‐ĸB signaling pathway plays a major role in kaempferol‐mediated alleviation of neuroinflammation. Quantitative real‐time polymerase chain reaction and flow cytometry were used to examine the modulator effect of kaempferol on microglial M1/M2 polarization. We found that kaempferol treatment can significantly reduce NP and proinflammatory cytokine production. Kaempferol attenuated the activation of TLR4/NF‐κB pathways in LPS‐activated BV2 cells. The analgesic effects of kaempferol on NP may be due to inhibition of microglia activation and switching the M1 to M2 phenotype.

23 October 2023 in Phytotherapy Research
Verified
Journal Article
Closed access
WSWaimei Si
Waimei Si
XLXin Li
Xin Li
BJBei Jing
Bei Jing
SCShiquan Chang
Shiquan Chang
YZYachun Zheng
Yachun Zheng
Di ZhangDi Zhang
Di Zhang

2 May 2022 in Phytotherapy Research
Verified
Journal Article
Open access
Di ZhangDi Zhang
Di Zhang
SCShiquan Chang
Shiquan Chang
XLXin Li
Xin Li
HSHuimei Shi
Huimei Shi
BJBei Jing
Bei Jing
GZGuoping Zhao
Guoping Zhao
Therapeutic drugs of chronic neuralgia have a high risk of addiction, making it crucial to identify novel drugs for chronic neuralgia. This study aimed to explore the therapeutic effect of paeoniflorin on chronic sciatica via inhibiting Schwann cell apoptosis. 28 SD rats were randomly divided into four groups, including the sham operation group, chronic constriction injury (CCI) group, mecobalamin group, and paeoniflorin group. The therapeutic effect and mechanism of paeoniflorin were evaluated via rat and cell experiments. Mechanical, hot, or cold hyperalgesia was induced in the rats after CCI operation, while paeoniflorin relieved chronic neuralgia. Besides, paeoniflorin decreased the levels of IL1, IL6, TNF‐α, CRP, and LPS and increased the level of IL10 in serum. As for the sciatic nerve, the number of inflammatory cells was decreased, and Schwann cells were present after paeoniflorin treatment, and paeoniflorin promoted the recovery of nerve structure. In cell experiments, LPS induced Schwann cell apoptosis via the TLR4/NF‐kB pathway. And paeoniflorin attenuated LPS‐induced Schwann cell apoptosis by decreasing the levels of TLR4, p‐NF‐kB, caspase3, cleaved‐caspase3, and cleaved‐caspase7. Overall, these results suggest that paeoniflorin alleviates chronic sciatica by decreasing inflammatory factor levels and promotes the repair of damaged nerves by reducing Schwann cell apoptosis.

1 January 2021 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
Di ZhangDi Zhang
Di Zhang
SCShiquan Chang
Shiquan Chang
BJBei Jing
Bei Jing
XLXin Li
Xin Li
HSHuimei Shi
Huimei Shi
GZGuoping Zhao
Guoping Zhao
Purpose. We explored the role of ROS in cold‐induced vasoconstriction and corresponding mechanism. Methods. Three experiments were performed. First, we measured blood flow in human hands before and after cold exposure. Second, 24 mice were randomly divided into 3 groups: 8 mice received saline injection, 8 received subcutaneous Tempol injection, and 8 received intrathecal Tempol injection. After 30 min, we determined blood flow in the skin before and after cold exposure. Finally, we used Tempol, CCG‐1423, and Go 6983 to pretreat HAVSMCs and HUVECs for 24 h. Then, cells in the corresponding groups were exposed to cold (6 h, 4°C). After cold exposure, the cytoskeleton was stained. Intracellular Ca2+ and ROS levels were measured by flow cytometry and fluorescence microscopy. We measured protein expression via Western blotting. Results. In the first experiment, after cold exposure, maximum skin blood flow decreased to 118.4 ± 50.97 flux units. Then, Tempol or normal saline pretreatment did not change skin blood flow. Unlike intrathecal Tempol injection, subcutaneous Tempol injection increased skin blood flow after cold exposure. Finally, cold exposure for 6 h shrank the cells, making them narrower, and increased intracellular Ca2+ and ROS levels in HUVECs and HAVSMCs. Tempol reduced cell shrinkage and decreased intracellular Ca2+ levels. In addition, Tempol decreased intracellular ROS levels. Cold exposure increased RhoA, Rock1, p‐MLC‐2, ET‐1, iNOS, and p‐PKC expression and decreased eNOS expression. Tempol or CCG‐1423 pretreatment decreased RhoA, Rock1, and p‐MLC‐2 levels in HAVSMCs. Furthermore, Tempol or Go 6983 pretreatment decreased ET‐1, iNOS, and p‐PKC expression and increased eNOS expression in HUVECs. Conclusion. ROS mediate the vasoconstrictor response within the cold‐induced vascular response, and ROS in blood vessel tissues rather than nerve fibers are involved in vasoconstriction via the ROS/RhoA/ROCK1 and ROS/PKC/ET‐1 pathways in VSMCs and endothelial cells.

11 April 2022 in Revista Brasileira de Farmacognosia
Verified
Journal Article
Closed access
PDF file
Di ZhangDi Zhang
Di Zhang
BJBei Jing
Bei Jing
XLXin Li
Xin Li
HSHuimei Shi
Huimei Shi
ZCZhenni Chen
Zhenni Chen
GZGuoping Zhao
Guoping Zhao

9 April 2025 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
SCShiquan Chang
Shiquan Chang
NDNana Ding
Nana Ding
YLYalin Li
Yalin Li
YLYing Li
Ying Li
ZTZiling Tang
Ziling Tang
JCJiaxu Chen
Jiaxu Chen
Background: Alzheimer's disease ( AD ) constitutes a devastating neurodegenerative disorder, manifested by amyloid‐β aggregation, phosphorylated tau accumulation, and progressive cognitive deterioration. Current therapeutic interventions remain predominantly symptomatic, underscoring the urgency for more efficacious treatment strategies. Purpose: This study elucidated the therapeutic potential of Sanshen San (SSS), a traditional Chinese herbal formula encompassing Polygala Radix , Pini Radix in Poria , and Acori Tatarinowii Rhizoma , on cognitive function and AD pathology. Methods: We implemented both acute Aβ 1‐42 ‐injected mice and 5xFAD transgenic mouse models. The therapeutic efficacy of SSS was assessed through behavioral paradigms including Y‐maze, Novel Object Recognition, and Morris Water Maze. Molecular mechanisms were delineated utilizing RNA sequencing, metabolomics analysis, immunofluorescence staining, Golgi‐Cox staining, transmission electron microscopy, and Western blotting. Results: Chemical analysis unveiled 10 principal bioactive compounds in SSS. The formula substantially ameliorated cognitive performance in both Aβ 1‐42 ‐injected and 5xFAD mouse models, attenuated Aβ plaque burden, and augmented microglial phagocytosis. SSS safeguarded synaptic integrity, enhanced mitochondrial function, and facilitated autophagy. Transcriptomic and metabolomic analyses demonstrated that SSS predominantly operates by reinstating synaptic transmission and neurotransmitter function, particularly in the dopaminergic system. Conclusion: SSS efficaciously mitigates AD pathology through potentiating synaptic function, optimizing mitochondrial homeostasis, and restoring neurotransmitter balance, exemplifying a promising multi‐target therapeutic strategy for the treatment of AD .